7. References related to instruments to measure outcome (as noted in 4 and 5 above)

Functional Living Index Emesis

Bonneterre, J., Schraub, S., Lecomte, S., & Mercier, M. (1996). Quality of life as an outcome in breast cancer. *Pharmacoeconomics, 9*(Suppl. 2), 23–29.

Crucitt, M.A., Hyman, W., Grote, T., Tester, W., Madajewicz, S., Yee, S., et al. (1996). Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of healthrelated quality of life. *Clinical Therapeutics, 18,* 778–788.

Farley, P.A., Dempsey, C.L., Shillington, A.A., Kulis-Robitaille, C., Colgan, K., & Bernstein, G. (1997). Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. *American Journal of Health-System Pharmacy, 54,* 2478–2482.

Lebeau,B., Depierre, A., Giovannini, M., Riviere, A., Kaluzinski, L., Votan B., et al. (1997). The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. *Annals of Oncology, 8,* 887–892.

Martin, A.R., Carides, A.D., Pearson, J.D., Horgan, K., Elmer, M., Schmidt, C. et al. (2003). Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. *European Journal of Cancer, 39,*1395–1401.

Satou, A., Yamazaki, T., Nukariya, N., Nakamachi, M., Shimada, K., Matsukawa, M., & Kurihara, M. (2002). Development of a Japanese version of the FLIE. *Gan to Kagaku Ryoho [Japanese Journal of Cancer and Chemotherapy], 29,* 281–291.

Sykes, A.J., Kiltie, A.E., & Stewart, A.L. (1997). Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. *Supportive Care in Cancer, 5,* 500–503.

Lindley, C.M., Hirsch, J.D., O'Neill, C.V., Transau, M.C., Gilbert, C.S., & Osterhaus, J.T.(1992). Quality of life consequences of chemotherapy-induced emesis. *Quality of Life Research, 1,* 331–340.

Morrow Assessment of Nausea

Alves-Guerreiro, J., Lowe-Strong, A.S., Walsh, D.M., Lopes, B.C., Costa, R., Rosado, R., et al. (2003). Development of a Portuguese version of the Morrow Assessment of Nausea and Emesis (MANE) Questionnaire: Moving physical therapy forward [Abstract]. *14th International World Confederation for Physical Therapy Congress.*

Crucitt, M.A., Hyman, W., Grote, T., Tester, W., Madajewicz, S., Yee, S., et al. (1996). Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. *Clinical Therapeutics, 18,* 508–518.

Hickok, J.T., Roscoe, J.A., Morrow, G.R., Stern, R.M., Yang, B., Flynn, P.J., et al. (1999). Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. *Cancer, 86,* 64–71.

Mantovani, G., Astara, G., Lampis, B., Bianchi, A., Curreli, L., Orru ,W., et al. (1996). Evaluation by multidimensional instruments of health-related quality of life of elderly cancer patients undergoing three different "psychosocial" treatment approaches. A randomized clinical trial. *Supportive Care in Cancer, 4,* 129–140.

Martin, C.G., Rubenstein, E.B., Elting, L.S., Kim, Y.J., & Osoba, D. (2003). Measuring chemotherapy-induced nausea and emesis. *Cancer, 98,* 645–655.

Molassiotis, A., Yung, H.P., Yam, B.M., Chan, F.Y., & Mok, T.S. (2002). The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: A randomised controlled trial. *Supportive Care in Cancer, 10,* 237–246.

Morrow, G. (1984). Assessment of nausea and vomiting: Past problems, current issues and suggestions for future research. *Cance*r, *53,* 2267-2278.

Roscoe, J.A., Morrow, G.R., Hickok, J.T., & Stern, R.M. (2000). Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. *Journal of Pain and Symptom Management, 20*, 113–121.

Index of Nausea and Vomiting

Arakawa, S. (1997). Relaxation to reduce nausea, vomiting, and anxiety induced by chemotherapy in Japanese patients. *Cancer Nursing, 20,* 342–349.

Dibble, S.L., Chapman, J., Mack, K.A., & Shih, A. (2000). Acupressure for nausea: Results of a pilot study. *Oncology Nursing Forum, 27,* 41–47. Oncology Nursing Forum

Dodd, M.J., Onishi, K., Dibble, S.L., & Larson, P.J. (1996). Differences in nausea, vomiting, and retching between younger and older outpatients receiving cancer chemotherapy. *Cancer Nursing, 19,* 155–161.

Fu, M.R., Rhodes, V., & Xu, B. (2002). The Chinese translation of the Index of Nausea,Vomiting, and Retching. *Cancer Nursing, 25,*134–140.

Lo, L.H. & Hayman, L.L. (1999). Parents associated with children in measuring acute and delayed nausea and vomiting. *Nursing and Health Sciences, 1,* 155–161.

Rhodes, V.A. & McDaniel R.W. (1999). The Index of Nausea, Vomiting, and Retching: a new format of the Index of Nausea and Vomiting. *Oncology Nursing Forum, 26*, 889–894. Oncology Nursing Forum